Genetically Modified Dendritic Cells for Cancer Immunotherapy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The ability to grow and differentiate dendritic cells (DC) ex vivo has allowed their genetic manipulation to enhance immune activation against tumor antigens. Gene engineering of DC can be achieved with a variety of physical methods and using different viral vectors. RNA or DNA transfection, either alone (naked), coated with liposomes or using electroporation or gene guns leads to T cell activation while transgene expression is frequently undetectable. Adenoviral and retroviral vectors have proven to be highly efficient in DC genetic modification, and have been widely used in preclinical models. Other vectors like lentivirus, poxvirus, herpes virus and adeno-associated virus (AAV) can also lead to foreign transgene expression in DC leading to immune cell activation. DC have been genetically engineered to provide constitutive and high level of tumor antigen expression or to introduce genes that further enhance their immune stimulatory ability. The promising results from preclinical animal models and from in vitro human immune cell culture systems have provided a strong rationale to initiate pilot clinical trials. Recently published or communicated clinical experiences and ongoing trials have used defined tumor antigen RNA transfection for prostate carcinoma and melanoma, liposome-encoated DNA transfection for breast or pancreatic cancer, adenoviral vector tumor antigen gene modification for melanoma and small cell lung cancer, and poxvirus-mediated expression of costimulatory molecules for colon carcinoma. These preliminary experiences suggest that genetically modified DC can safely induce T cell responses but few clinical responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359 · cited 2×
“A clinical trial administering DC transfected with human telomerase mRNA by electroporation to patients with prostate cancer has been reported [Su et al., 2005].”
MethodDendritic and Natural Killer Cells Cooperate in the Control/Switch of Innate Immunity
Zitvogel, L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012040 · Cited by 268
Morse, M. A., Nair, S. K., Mosca, P. J., Hobeika, A. C., Clay, T. M., Deng, Y., Boczkowski, D., Proia, A., Neidzwiecki, D., Clavien#, P.-A., et al. (2003) · Cancer Investigation · doi:10.1081/cnv-120018224 · Cited by 177
Caruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165 · cited 1×
“Dendritic cells pulsed with tumor-derived RNA were administered to 7 pediatric and young adults with a variety of brain tumors within a phase I trial [Caruso et al., 2004].”
MethodCaruso, D. A., Orme, L. M., Amor, G. M., Neale, A. M., Radcliff, F. J., Downie, P., Tang, M. L. K., & Ashley, D. M. (2005) · Cancer · doi:10.1002/cncr.20911 · Cited by 106 · cited 1×
“The same group conducted a study of tumorderived RNA pulsed DC in patients with neuroblastoma [Caruso et al., 2005].”
Background
Cited by
Immune Responses to Lentiviral Vectors
Follenzi, A., Santambrogio, L., & Annoni, A. (2007) · Current Gene Therapy · doi:10.2174/156652307782151515 · Cited by 87
Xin, K.-Q., Mizukami, H., Urabe, M., Toda, Y., Shinoda, K., Yoshida, A., Oomura, K., Kojima, Y., Ichino, M., Klinman, D., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00890-06 · Cited by 81
“A number of studies show that recombinant AAV vectors can be used to transduce DCs (2, 13, 32, 35, 39, 46, 49, 53, 70).”
BackgroundFerrand, M., Galy, A., & Boisgerault, F. (2014) · Gene Therapy · doi:10.1038/gt.2014.61 · Cited by 21
Metadata
- Authors
- Ribas, A.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-12-01
- Volume
- 5
- Issue
- 6
- Pages
- 619-628
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2125113646
- Cited by
- 63
- References
- 7
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetically Modified Dendritic Cells for Cancer Immunotherapy. https://app.cochat.ai/papers/10.2174/156652305774964758
- The paper
- Ribas, A. (2005). Genetically Modified Dendritic Cells for Cancer Immunotherapy. Current Gene Therapy. https://doi.org/10.2174/156652305774964758
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.